Company Overview

Interpace Biosciences, Inc. is a precision diagnostics company operating in the molecular diagnostics and anatomic pathology industries, with a primary focus on improving clinical decision-making for patients with cancer and other complex diseases. The company develops, commercializes, and performs diagnostic tests that combine molecular analysis with clinical and pathological information to guide diagnosis and treatment decisions.

The company’s core revenue is generated from proprietary diagnostic tests used primarily in thyroid, pancreatic, and other solid tumor assessments. Its key customers include hospitals, physician practices, academic medical centers, and integrated healthcare systems. Interpace Biosciences positions itself through specialized expertise in difficult-to-diagnose conditions, particularly indeterminate thyroid nodules, where traditional cytology alone may be insufficient.

Interpace Biosciences traces its origins to 1986 and has undergone multiple strategic transformations, including divestitures and refocusing efforts, to concentrate on high-value molecular diagnostics. The company became publicly traded through its predecessor entities and has since narrowed its strategy toward specialized diagnostic services with strong clinical utility and reimbursement support.

Business Operations

Interpace Biosciences operates primarily through its clinical laboratory business, delivering molecular diagnostic testing services. Its major business activities include the development and commercialization of proprietary assays such as ThyGeNEXT, ThyraMIR, PanDNA, and PancraGEN, which are designed to improve diagnostic accuracy for thyroid nodules and pancreatic cysts. Revenue is primarily generated on a per-test basis through third-party reimbursement and direct billing to healthcare providers.

The company conducts its laboratory operations in the United States and does not manufacture physical diagnostic kits for broad distribution, instead operating under a centralized laboratory service model. Interpace controls its testing technologies, intellectual property, and laboratory infrastructure. It has historically engaged in limited strategic partnerships and licensing arrangements related to biomarker discovery and assay development. Data regarding active joint ventures is inconclusive based on available public sources.

Strategic Position & Investments

Interpace Biosciences’ strategic direction centers on expanding adoption of its core diagnostic assays, improving reimbursement coverage, and advancing next-generation molecular and genomic testing solutions. The company has emphasized leveraging its existing physician relationships and clinical data to drive test utilization while managing operating costs in a highly regulated reimbursement environment.

Historically, Interpace has pursued targeted acquisitions and asset purchases to strengthen its diagnostic portfolio, including the acquisition of Asuragen’s thyroid diagnostics assets, which expanded its thyroid testing capabilities. The company continues to invest in assay development, bioinformatics, and evidence generation to support clinical utility. Public disclosures indicate selective investment in emerging molecular technologies, though details on early-stage pipeline assets are limited and data remains inconclusive based on available public sources.

Geographic Footprint

Interpace Biosciences is headquartered in the United States and conducts the majority of its operations domestically. Its laboratory services primarily support healthcare providers across North America, with testing samples submitted from hospitals and clinics nationwide.

While the company does not maintain significant physical operations outside the United States, its diagnostic services may indirectly support international patients treated within U.S.-based healthcare systems. Publicly available filings do not indicate material international laboratory operations or foreign subsidiaries, and international revenue contribution appears immaterial based on available disclosures.

Leadership & Governance

Interpace Biosciences is led by an executive team with experience in molecular diagnostics, laboratory operations, and healthcare commercialization. The leadership team emphasizes operational discipline, clinical evidence generation, and strategic focus on high-value diagnostic niches.

Key executives include:

• David R. King – President and Chief Executive Officer
• Thomas P. Burns – Chief Financial Officer
• Jacki Hoskings – Senior Vice President, Clinical & Regulatory Affairs
• Michael Gardner – Vice President, Sales and Marketing

The company operates under a board-governed structure typical of U.S. public life sciences companies, with oversight of strategy, risk management, and regulatory compliance. Management has consistently articulated a strategy centered on precision diagnostics, reimbursement stability, and sustainable growth within specialized clinical markets.

Verification Requirements

All information presented is based on publicly available data verified across multiple reputable sources, including SEC filings, company investor disclosures, and major financial and healthcare industry publications. Where public disclosures lack sufficient detail or present inconsistencies, this has been explicitly noted as inconclusive based on available public sources.